BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 34221399)

  • 1. Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab.
    Menzella F; Galeone C; Ghidoni G; Ruggiero P; Capobelli S; Simonazzi A; Catellani C; Scelfo C; Livrieri F; Facciolongo N
    Multidiscip Respir Med; 2021 Jan; 16(1):779. PubMed ID: 34221399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
    Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
    Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis.
    Koga Y; Aoki-Saito H; Kamide Y; Sato M; Tsurumaki H; Yatomi M; Ishizuka T; Hisada T
    Front Pharmacol; 2022; 13():865318. PubMed ID: 35359852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis.
    Matsuno O; Minamoto S
    Respir Med Case Rep; 2022; 40():101763. PubMed ID: 36353062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-IL5 Monoclonal Antibodies Reduce Asthma Exacerbations and Corticosteroids Dose in Three Eosinophilic Granulomatosis with Polyangiitis Case Reports.
    Skouvaklidou E; Kipourou M; Zisopoulos D; Vounotrypidis P; Katsoulis K
    Mediterr J Rheumatol; 2023 Jun; 34(2):238-244. PubMed ID: 37654647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eosinophilic granulomatosis with polyangitis: A new target for biologicals.
    Bayrak Durmaz MS; Çelebi Sözener Z; Bavbek S
    Tuberk Toraks; 2022 Mar; 70(1):93-101. PubMed ID: 35362309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis.
    Guntur VP; Manka LA; Denson JL; Dunn RM; Dollin YT; Gill M; Kolakowski C; Strand MJ; Wechsler ME
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1186-1193.e1. PubMed ID: 33065367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis.
    Desaintjean C; Ahmad K; Traclet J; Gerfaud-Valentin M; Durel CA; Glerant JC; Hot A; Lestelle F; Mainbourg S; Nasser M; Seve P; Turquier S; Devouassoux G; Cottin V
    Front Med (Lausanne); 2024; 11():1341310. PubMed ID: 38585151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Report: Severe Eosinophilic Asthma Associated With ANCA-Negative EGPA in a Young Adult Successfully Treated With Benralizumab.
    Ricciardi L; Soler DG; Bennici A; Brunetto S; Pioggia G; Gangemi S
    Front Pharmacol; 2022; 13():858344. PubMed ID: 35462932
    [No Abstract]   [Full Text] [Related]  

  • 10. Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis.
    Vultaggio A; Nencini F; Bormioli S; Vivarelli E; Dies L; Rossi O; Parronchi P; Maggi E; Matucci A
    Allergy Asthma Immunol Res; 2020 Sep; 12(5):885-893. PubMed ID: 32638567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy.
    Faverio P; Bonaiti G; Bini F; Vaghi A; Pesci A
    Ther Clin Risk Manag; 2018; 14():2385-2396. PubMed ID: 30573961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful Treatment of Eosinophilic Granulomatosis With Polyangiitis: A Case of Refractory Peripheral Neuropathy and Comorbid Chronic Progressive Pulmonary Aspergillosis Treated With Mepolizumab.
    Sekiya R; Soma T; Nakagome K; Nagata M
    Cureus; 2024 Jan; 16(1):e52192. PubMed ID: 38222984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of benralizumab in a patient with uncontrolled severe eosinophilic asthma and comorbid chronic rhinosinusitis with nasal polyps refractory to mepolizumab treatment.
    Mansur AH
    Respir Med Case Rep; 2022; 35():101559. PubMed ID: 34976716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series.
    Detoraki A; Tremante E; Poto R; Morelli E; Quaremba G; Granata F; Romano A; Mormile I; Rossi FW; de Paulis A; Spadaro G
    Respir Res; 2021 Jun; 22(1):185. PubMed ID: 34162391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis.
    Nagase H; Ueki S; Fujieda S
    Allergol Int; 2020 Apr; 69(2):178-186. PubMed ID: 32139163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term Safety and Efficacy of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis Complicated with Severe Neuropathy.
    Koga Y; Yoshimi S; Harada T; Suzuki S; Ohtsuka T; Dobashi K; Hisada T
    Intern Med; 2023 May; 62(10):1553-1556. PubMed ID: 36171130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benralizumab in the management of rare primary eosinophilic lung diseases.
    Griscti Soler D; Bennici A; Brunetto S; Gangemi S; Ricciardi L
    Allergy Asthma Proc; 2022 Nov; 43(6):494-500. PubMed ID: 36335418
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities.
    Berti A; Atzeni F; Dagna L; Del Giacco S; Emmi G; Salvarani C; Vaglio A
    Ann Rheum Dis; 2023 Feb; 82(2):164-168. PubMed ID: 36357156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [SUCCESSFUL TREATMENT FOR OTITIS MEDIA AND SINUSITIS ASSOCIATED WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS USING ANTI-IL-5 RECEPTOR MONOCLONAL ANTIBODY BENRALIZUMAB].
    Sugiyama T; Yoshida S; Kikuchi S; Iino Y
    Arerugi; 2022; 71(3):242-247. PubMed ID: 35569946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
    McBrien CN; Menzies-Gow A
    Drugs Today (Barc); 2018 Feb; 54(2):93-101. PubMed ID: 29637936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.